PLP2

Summary

PLP2 (proteolipid protein 2, HGNC:9087) is a protein-coding gene on chromosome Xp11.23, encoding Proteolipid protein 2 (Q04941). May play a role in cell differentiation in the intestinal epithelium.

This gene encodes an integral membrane protein that localizes to the endoplasmic reticulum in colonic epithelial cells. The encoded protein can multimerize and may function as an ion channel. A polymorphism in the promoter of this gene may be linked to an increased risk of X-linked cognitive disability. A pseudogene of this gene is found on chromosome 5.

Source: NCBI Gene 5355 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 46 total
• Druggable target: yes
• MANE Select transcript: NM_002668

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9087
Approved symbol	PLP2
Name	proteolipid protein 2
Location	Xp11.23
Locus type	gene with protein product
Status	Approved
Aliases	A4, A4-LSB, MGC126187
Ensembl gene	ENSG00000102007
Ensembl biotype	protein_coding
OMIM	300112
Entrez	5355

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000376322, ENST00000376327, ENST00000879549, ENST00000935268

RefSeq mRNA: 1 — MANE Select: NM_002668 NM_002668

CCDS: CCDS14319

Canonical transcript exons

ENST00000376327 — 5 exons

Exon	Start	End
ENSE00000670265	49174335	49174425
ENSE00000670267	49173388	49173483
ENSE00000670269	49173129	49173281
ENSE00001470203	49174672	49175235
ENSE00003851018	49171898	49172096

Expression profiles

Bgee: expression breadth ubiquitous, 267 present calls, max score 99.43.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 190.9998 / max 3605.2796, expressed in 1788 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196320	114.5359	1777
196319	39.8478	1717
196321	36.6161	1681

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	99.43	gold quality
gingiva	UBERON:0001828	99.35	gold quality
skin of abdomen	UBERON:0001416	99.24	gold quality
descending thoracic aorta	UBERON:0002345	99.20	gold quality
esophagus mucosa	UBERON:0002469	99.17	gold quality
skin of leg	UBERON:0001511	99.16	gold quality
right coronary artery	UBERON:0001625	99.13	gold quality
thoracic aorta	UBERON:0001515	99.10	gold quality
ascending aorta	UBERON:0001496	99.09	gold quality
zone of skin	UBERON:0000014	99.08	gold quality
aorta	UBERON:0000947	99.05	gold quality
nipple	UBERON:0002030	99.05	gold quality
popliteal artery	UBERON:0002250	99.04	gold quality
tibial artery	UBERON:0007610	99.04	gold quality
upper leg skin	UBERON:0004262	99.03	gold quality
body of pancreas	UBERON:0001150	99.00	gold quality
tongue squamous epithelium	UBERON:0006919	98.98	gold quality
lower esophagus mucosa	UBERON:0035834	98.97	gold quality
pharyngeal mucosa	UBERON:0000355	98.96	gold quality
penis	UBERON:0000989	98.95	gold quality
vagina	UBERON:0000996	98.92	gold quality
mammalian vulva	UBERON:0000997	98.92	gold quality
esophagus	UBERON:0001043	98.91	gold quality
skin of hip	UBERON:0001554	98.88	gold quality
left coronary artery	UBERON:0001626	98.87	gold quality
mucosa of stomach	UBERON:0001199	98.80	gold quality
left adrenal gland cortex	UBERON:0035825	98.78	gold quality
monocyte	CL:0000576	98.76	gold quality
left adrenal gland	UBERON:0001234	98.76	gold quality
right adrenal gland	UBERON:0001233	98.72	gold quality

Single-cell (SCXA)

Detected in 23 experiment(s), a significant marker in 19.

Experiment	Marker?	Max mean expression
E-MTAB-7407	yes	589.97
E-CURD-112	yes	465.65
E-MTAB-6701	yes	89.92
E-CURD-114	yes	72.29
E-HCAD-4	yes	67.75
E-HCAD-6	yes	62.05
E-GEOD-125970	yes	24.91
E-MTAB-10042	yes	16.56
E-MTAB-9467	yes	16.38
E-HCAD-10	yes	15.30
E-MTAB-9067	yes	15.21
E-MTAB-8498	yes	13.38
E-CURD-122	yes	13.32
E-CURD-46	yes	10.15
E-GEOD-135922	yes	9.98

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting PLP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-1273H-3P	99.29	67.55	980
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4777-3P	99.15	68.92	626
HSA-MIR-6768-3P	99.14	67.38	1319
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-1843	98.97	66.07	838

Literature-anchored findings (GeneRIF, showing 16)

• PLP2/A4 has a role in the chemotactic processes via CCR1 (PMID:15474493)
• PLP2 is expressed abundantly in the pyramidal cells of hippocampus and granular cells of the cerebellum in the brains of a cohort of males with probable X-linked mental retardation. (PMID:17416750)
• This work ascribes a critical function to PLP2 for viral ligase activity and underlines the power of non-lethal haploid genetic screens in human cells to identify the genes involved in pathogen manipulation of the host immune system. (PMID:24278019)
• PLP2 and RAB5C are binding partners of TPD52. (PMID:24604726)
• PLP2 specifically binds to phosphatidylinositol 3 kinase to activate the protein kinase B pathway to enhance cell proliferation, adhesion, and invasion in melanoma cells. (PMID:26287415)
• Up-regulation of miR-422a attenuated microsphere formation, proliferation and tumor formation of breast cancer stem cells via suppressing the PLP2 expression. (PMID:29509055)
• Higher PLP2 immunohistochemistry staining significantly correlated with more advanced tumor grades and poorer prognosis in human gliomas. (PMID:30373180)
• Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma. (PMID:31778016)
• MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. (PMID:31901870)
• PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. (PMID:32596309)
• CD45RO(-)CD8(+) T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERbeta/miR-765/PLP2/Notch axis. (PMID:33859750)
• PLP2 drives collective cell migration via ZO-1-mediated cytoskeletal remodeling at the leading edge in human colorectal cancer cells. (PMID:34409455)
• PLP2-derived peptide Rb4 triggers PARP-1-mediated necrotic death in murine melanoma cells. (PMID:35190586)
• Structural basis of plp2-mediated cytoskeletal protein folding by TRiC/CCT. (PMID:36921056)
• Low Expression of A3C and PLP2 Indicating a Favorable Prognosis in Human Gliomas. (PMID:37715423)
• Reduced Proteolipid Protein 2 promotes endoplasmic reticulum stress-related apoptosis and increases drug sensitivity in acute myeloid leukemia. (PMID:38085372)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	plp2b	ENSDARG00000036630
danio_rerio	plp2a	ENSDARG00000042972
mus_musculus	Plp2	ENSMUSG00000031146
mus_musculus	Plp2rt	ENSMUSG00000057762
rattus_norvegicus	Plp2	ENSRNOG00000039496
rattus_norvegicus	Plp2l1	ENSRNOG00000055728
caenorhabditis_elegans	F28H1.4	WBGENE00017909
caenorhabditis_elegans	F47B3.3	WBGENE00018527

Paralogs (14): CMTM1 (ENSG00000089505), CMTM6 (ENSG00000091317), PLLP (ENSG00000102934), CMTM3 (ENSG00000140931), CMTM2 (ENSG00000140932), MALL (ENSG00000144063), MAL2 (ENSG00000147676), CMTM7 (ENSG00000153551), MARVELD1 (ENSG00000155254), CMTM5 (ENSG00000166091), CMTM8 (ENSG00000170293), MAL (ENSG00000172005), CMTM4 (ENSG00000183723), CKLF (ENSG00000217555)

Protein

Protein identifiers

Proteolipid protein 2 — Q04941 (reviewed: Q04941)

Alternative names: Differentiation-dependent protein A4, Intestinal membrane A4 protein

All UniProt accessions (1): Q04941

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in cell differentiation in the intestinal epithelium.

Subcellular location. Membrane.

Tissue specificity. Enriched in colonic mucosa. The expression of A4 follows a gradient along the crypto-villus axis with the most abundant message occurring in the lower half of the crypt.

Isoforms (2)

UniProt ID	Names	Canonical?
Q04941-1	1	yes
Q04941-2	2

RefSeq proteins (1): NP_002659* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008253	Marvel	Domain
IPR050578	MARVEL-CKLF_proteins	Family

Pfam: PF01284

UniProt features (10 total): transmembrane region 4, glycosylation site 2, chain 1, domain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q04941-F1	78.76	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 18, 108

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 314 (showing top): RNGTGGGC_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, HORIUCHI_WTAP_TARGETS_DN, GOBP_RESPONSE_TO_PEPTIDE, XU_GH1_AUTOCRINE_TARGETS_UP, JAEGER_METASTASIS_DN, MODULE_151, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, HSIAO_HOUSEKEEPING_GENES, GGGTGGRR_PAX4_03, AAAYRNCTG_UNKNOWN, TTGGGAG_MIR150

GO Biological Process (4): monoatomic ion transport (GO:0006811), chemotaxis (GO:0006935), cytokine-mediated signaling pathway (GO:0019221), monoatomic ion transmembrane transport (GO:0034220)

GO Molecular Function (3): monoatomic ion transmembrane transporter activity (GO:0015075), chemokine binding (GO:0019956), protein binding (GO:0005515)

GO Cellular Component (4): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	1
response to chemical	1
taxis	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
monoatomic ion transport	1
transmembrane transport	1
transmembrane transporter activity	1
monoatomic ion transmembrane transport	1
cytokine binding	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

738 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLP2	PLP1	P04400	995
PLP2	PDCL2	Q8N4E4	894
PLP2	PDCL3	Q9H2J4	840
PLP2	BECN1	Q14457	774
PLP2	IRF3	Q14653	701
PLP2	TUBB2A	Q13885	649
PLP2	TUBB	P05218	642
PLP2	TCP1	P17987	588
PLP2	SH2D3C	Q8N5H7	572
PLP2	ZUP1	Q96AP4	553
PLP2	PPP1CA	P08129	547
PLP2	PDC	P20941	532
PLP2	SH2D3A	Q9BRG2	479
PLP2	ISG15	P05161	476
PLP2	USP2	O75604	444

IntAct

227 interactions, top by confidence:

A	B	Type	Score
TMEM79	PLP2	psi-mi:“MI:0915”(physical association)	0.670
PLP2	TMEM79	psi-mi:“MI:0915”(physical association)	0.670
TMPRSS2	PLP2	psi-mi:“MI:0915”(physical association)	0.600
PLP2	KASH5	psi-mi:“MI:0915”(physical association)	0.560
KASH5	PLP2	psi-mi:“MI:0915”(physical association)	0.560
PLP2	HSD17B13	psi-mi:“MI:0915”(physical association)	0.560
PLP2	TMEM51	psi-mi:“MI:0915”(physical association)	0.560
PLP2	CYB561	psi-mi:“MI:0915”(physical association)	0.560
PLP2	SCN3B	psi-mi:“MI:0915”(physical association)	0.560
PLP2	ELOVL5	psi-mi:“MI:0915”(physical association)	0.560
PLP2	LHFPL5	psi-mi:“MI:0915”(physical association)	0.560
PLP2		psi-mi:“MI:0915”(physical association)	0.560
ARFIP2	PLP2	psi-mi:“MI:0915”(physical association)	0.560
PLP2	FATE1	psi-mi:“MI:0915”(physical association)	0.560
HSBP1L1	PLP2	psi-mi:“MI:0915”(physical association)	0.560
PLP2	RNF5	psi-mi:“MI:0915”(physical association)	0.560
PLP2	SLC14A2	psi-mi:“MI:0915”(physical association)	0.560
ASGR2	PLP2	psi-mi:“MI:0915”(physical association)	0.560
PLP2	BNIP3	psi-mi:“MI:0915”(physical association)	0.560
PLP2	BIK	psi-mi:“MI:0915”(physical association)	0.560
PLP2	PACC1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (120): TMEM79 (Two-hybrid), CCDC155 (Two-hybrid), PLP2 (Affinity Capture-MS), PLP2 (Affinity Capture-MS), PLP2 (Proximity Label-MS), PLP2 (Affinity Capture-MS), PLP2 (Affinity Capture-MS), PLP2 (Affinity Capture-RNA), PLP2 (Two-hybrid), PLP2 (Two-hybrid), PLP2 (Affinity Capture-MS), PLP2 (Synthetic Lethality), PLP2 (Two-hybrid), PLP2 (Two-hybrid), PLP2 (Two-hybrid)

ESM2 similar proteins: A2VE13, A4K2N5, A4K2W1, B8BPI2, E1BY51, O09117, O09198, O35682, O62646, O88662, O89104, P21145, Q04941, Q10EJ2, Q16563, Q1RMQ3, Q28296, Q3URJ8, Q3ZBY0, Q5R6H1, Q5RAI2, Q5VXT5, Q64349, Q6DHB5, Q6GPN9, Q6P0C6, Q6P742, Q6VBQ5, Q6Y1E2, Q78S06, Q86TG1, Q86UW1, Q8BI08, Q8CJ61, Q8IZ96, Q8IZR5, Q8N2H4, Q8N8D7, Q91WN2, Q95MN6

Diamond homologs: Q04941, Q28597, Q6P742, Q6Y1E2, Q95MN6, Q96DZ9, Q99LJ5, Q9D6G9, Q9R1Q7, Q96MX0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

811 predictions. Top by Δscore:

Variant	Effect	Δscore
X:49172074:G:T	donor_gain	1.0000
X:49172093:GATT:G	donor_gain	1.0000
X:49172097:G:GG	donor_gain	1.0000
X:49173277:GGAGT:G	donor_gain	1.0000
X:49173278:GAGT:G	donor_gain	1.0000
X:49173278:GAGTG:G	donor_gain	1.0000
X:49173280:GT:G	donor_gain	1.0000
X:49173282:G:GG	donor_gain	1.0000
X:49173380:C:G	acceptor_gain	1.0000
X:49173383:CACA:C	acceptor_loss	1.0000
X:49173385:CA:C	acceptor_loss	1.0000
X:49173386:A:AT	acceptor_loss	1.0000
X:49173387:G:C	acceptor_loss	1.0000
X:49173481:GGG:G	donor_gain	1.0000
X:49173482:GGG:G	donor_gain	1.0000
X:49173523:GGTT:G	donor_gain	1.0000
X:49173668:G:T	donor_gain	1.0000
X:49174325:T:A	acceptor_gain	1.0000
X:49174329:CCCCA:C	acceptor_loss	1.0000
X:49174330:CCCA:C	acceptor_loss	1.0000
X:49174331:CCAGG:C	acceptor_loss	1.0000
X:49174332:CAGGT:C	acceptor_loss	1.0000
X:49174333:A:C	acceptor_loss	1.0000
X:49174333:AG:A	acceptor_gain	1.0000
X:49174334:GG:G	acceptor_gain	1.0000
X:49174422:ACTGG:A	donor_loss	1.0000
X:49174426:G:GG	donor_gain	1.0000
X:49172073:G:GT	donor_gain	0.9900
X:49172095:TT:T	donor_gain	0.9900
X:49173125:CCA:C	acceptor_loss	0.9900

AlphaMissense

974 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:49174341:G:C	G118R	0.984
X:49172073:G:A	G25R	0.983
X:49172073:G:C	G25R	0.983
X:49173270:T:A	W80R	0.983
X:49173270:T:C	W80R	0.983
X:49173410:C:A	A91E	0.983
X:49173135:T:C	C35R	0.981
X:49173398:G:C	R87P	0.977
X:49173279:A:C	S83R	0.974
X:49173281:T:A	S83R	0.974
X:49173281:T:G	S83R	0.974
X:49173137:C:G	C35W	0.972
X:49174342:G:A	G118D	0.972
X:49174365:G:C	G126R	0.972
X:49173481:G:A	G115R	0.968
X:49173481:G:C	G115R	0.968
X:49174366:G:A	G126D	0.968
X:49173482:G:A	G115E	0.965
X:49173156:T:C	F42L	0.962
X:49173158:C:A	F42L	0.962
X:49173158:C:G	F42L	0.962
X:49173272:G:C	W80C	0.962
X:49173272:G:T	W80C	0.962
X:49174375:C:A	A129D	0.960
X:49172074:G:A	G25E	0.958
X:49174356:T:C	C123R	0.958
X:49172083:T:C	L28P	0.957
X:49172093:G:C	E31D	0.956
X:49172093:G:T	E31D	0.956
X:49173136:G:A	C35Y	0.956

dbSNP variants (sampled 300 via entrez): RS1000441232 (X:49172441 G>A), RS1000822608 (X:49174266 C>A), RS1001940945 (X:49173716 G>A,C), RS1004391357 (X:49171018 C>T), RS1004675270 (X:49173571 G>A,T), RS1004726216 (X:49173171 C>A,T), RS1006399805 (X:49175392 G>A), RS1008198471 (X:49170449 C>T), RS1011837805 (X:49169933 C>G), RS1013098987 (X:49172001 A>C,G), RS1013157305 (X:49171397 C>G,T), RS1013440986 (X:49174217 G>A), RS1014759412 (X:49173616 G>C), RS1014863204 (X:49172648 G>T), RS1016540890 (X:49174926 A>G)

Disease associations

OMIM: gene MIM:300112 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002401_287	Platelet distribution width	9.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067398 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	9
Cadmium Chloride	increases palmitoylation, decreases expression, increases expression, decreases reaction, increases abundance	3
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
entinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Cadmium	decreases expression, decreases reaction, increases abundance, increases palmitoylation	2
Doxorubicin	affects expression, decreases expression	2
Tretinoin	decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
salinomycin	decreases expression	1
beta-lapachone	increases expression	1
methylparaben	increases expression	1
sodium arsenite	increases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
cadmium acetate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CD 437	decreases expression	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	increases expression	1
Temozolomide	decreases expression	1
Decitabine	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	decreases expression	1
Atrazine	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652069	Binding	Binding affinity to human PLP2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TE70	HAP1 PLP2 (-) 1	Cancer cell line	Male
CVCL_TE71	HAP1 PLP2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.